
DY-131
CAS No. 95167-41-2
DY-131 ( DY131 | DY-131 | DY 131 | GSK-9089 )
产品货号. M17689 CAS No. 95167-41-2
DY131 是一种新型选择性 ERRβ 和 ERRγ 激动剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥381 | 有现货 |
![]() ![]() |
10MG | ¥648 | 有现货 |
![]() ![]() |
25MG | ¥1264 | 有现货 |
![]() ![]() |
50MG | ¥2341 | 有现货 |
![]() ![]() |
100MG | ¥3686 | 有现货 |
![]() ![]() |
200MG | ¥5127 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称DY-131
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述DY131 是一种新型选择性 ERRβ 和 ERRγ 激动剂。
-
产品描述DY131, also known as GSK-9089, is a novel selective agonist at estrogen-related receptors ERRβ and ERRγ. DY131 could potentiate the ERRgamma-induced growth inhibition in LNCaP-ERRgamma and DU145-ERRgamma cells in a dose-dependent manner. ERRgamma may perform an antiproliferative or tumor-suppressing function in prostate cancer cells. ERRgamma could be a novel therapeutic target for prostate cancer treatment.
-
体外实验DY131 (0.1-30 μM; 5 days) treatment suppresses cell proliferation and reduces BrdUrd-positive cells in both LNCaP-ERRγ and LNCaP cells in a dose-dependent manner, with higher suppression in LNCaP-ERRγ clone.DY131 inhibits Shh induced accumulation of Smo::EGFP with an IC50 of 0.8 μM. DY131 suppresses SAG (100 nM) induced accumulation of Smo EGFP in the primary cilium and Gli transcription activity with an IC50 of ~2 μM.DY131 dramatically decreases phosphorylated histone H3 (pH3) marked proliferation of CGNPs induced by Shh. A selective ERRγ agonist, DY131, inhibits the growth of the ERα-positive endometrial cancer cells but promoted that of the ERα-negative cancer cells. Cell Proliferation Assay Cell Line:LNCaP-ERRγ and LNCaP cells Concentration:0.1 μM, 1 μM, 10 μM, 30 μM Incubation Time:5 days Result:Suppressed cell proliferation and reduced BrdUrd-positive cells in both LNCaP-ERRγ and LNCaP cells in a dose-dependent manner.
-
体内实验DY131 (5 μg/kg; subcutaneous injection; every second day; for 12 days) treatment increases P450 side-chain cleavage (P450scc), StAR and HMGCoA reductase (HMGCR) while decreases hormone sensitive lipase (HSL) expressions. Animal Model:Mature male mice (C57BL/6) (8-10 week-old; ~24.3 g) Dosage:5 μg/kg Administration:Subcutaneous injection; every second day; for 12 days Result:Increased P450scc, StAR and HMGCR while decreased HSL expressions.
-
同义词DY131 | DY-131 | DY 131 | GSK-9089
-
通路Tyrosine Kinase
-
靶点Ephrin Receptor
-
受体ERRβ| ERRγ
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number95167-41-2
-
分子量311.38
-
分子式C18H21N3O2
-
纯度>98% (HPLC)
-
溶解度DMSO : 50 mg/mL. 160.58 mM;
-
SMILESC(=O)(c1ccc(cc1)O)N/N=C/c1ccc(cc1)N(CC)CC
-
化学全称(E)-N'-(4-(diethylamino)benzylidene)-4-hydroxybenzohydrazide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Wang Y, et al. ACS Chem Biol. 2012,15;7(6):1040-8.2. Kumar P, et al. Mol Endocrinol. 2011;25(9): 1513-26.
产品手册




关联产品
-
NVP-BHG712
NVP-BHG712 是一种特异性 EphB4 抑制剂,ED50 为 25 nM,可区分 VEGFR 和 EphB4 抑制。
-
AI-10-49
AI-10-49 是 CBFβ-SMMHC 与 RUNX1 结合的选择性抑制剂,IC50 为 260 nM。
-
NVP-BHG712 isomer
NVP-BHG712 异构体显示出与 EPHA2 和 EPHB4 的保守非键合。